Provectus Pharmaceuticals, Inc. and Its Subsidiaries absolute Unregistered ... MarketWatch (press release) Its dermatological drug PH-10 also targets aberrant or diseased cells, with the current focus connected psoriasis and atopic dermatitis. Provectus has recently realized Phase 2 trials of PV-10 as a medical aid for metastatic melanoma, and of PH-10 as type A topical ... and more » Link To Article
No comments:
Post a Comment